- Atea Pharmaceuticals press release (NASDAQ:AVIR): Q4 GAAP EPS of -$0.41 beats by $0.04.
Cash, Cash Equivalents and Marketable Securities: $646.7 million at December 31, 2022 compared to $764.4 million at December 31, 2021.
- Interest Income and Other, Net: Interest income and other, net was $5.6 million and $11.2 million for the fourth quarter and full year 2022, respectively, compared to less than $0.1 million and $0.2 million for the corresponding periods in 2021.
Recommended For You
More Trending News
See More »